RxDoctor Payments Data

Carol Crase, APRN

Family · Louisville, KYNPI 1033414370

Payments from drug & device makers

$833in general payments, 2019–2025

Across 22 payments — averaging $37.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$296
  • Si-bone, Inc.$229
  • AbbVie$99
  • Protega Pharmaceutials Inc$46
  • Johnson & Johnson$37
  • Boston Scientific$27
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$48,935
Medicare patients
284
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate13$11,647
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen208$5,298
Lidocaine11$2,118
Gabapentin189$1,440
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen41$1,363
Tizanidine Hcl109$571
Baclofen40$461
Morphine Sulfate ErMorphine Sulfate17$409
Tramadol Hcl53$316
Methocarbamol23$315
Methylprednisolone58$290
Cyclobenzaprine Hcl46$238
Pregabalin14$110
Ibuprofen18$107
Amitriptyline Hcl15$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$14$11,64713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →